Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IRL 201104

Next Previous
Drug Profile

IRL 201104

Alternative Names: '1104; ILR 201104; IRL1104; IRL201104; PIN-201104

Latest Information Update: 18 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kings College London; Peptinnovate; St. Georges University of London
  • Developer Revolo Biotherapeutics
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Eosinophilic oesophagitis; Seasonal allergic rhinitis
  • Phase I Asthma
  • Preclinical Adult respiratory distress syndrome; Atopic dermatitis

Most Recent Events

  • 05 Aug 2025 Preclinical trials in Atopic dermatitis in United Kingdom (Sublingual)
  • 05 Aug 2025 Pharmacodynamics data from preclinical trials in Atopic dermatitis released by Revolo Biotherapeutics
  • 05 Aug 2025 Revolo Biotherapeutics plans clinical trial in Atopic dermatitis in 2026 (Sublingual)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top